Modus Therapeutics: SEVUSMART study of sevuparin in children with severe malaria published in Nature Communications

https://www.news-medical.net/news/20261022/Modus-Therapeutics-SEVUSMART-study-of-sevuparin-in-children-with-severe-malaria-published-in-Nature-Communications.aspx Modus Therapeutics Holding AB (publ) announces that the manuscript based on the Phase Ib study SEVUSMART in severe malaria, lead-authored by Professor Kathryn Maitland of Imperial College London with co-authors from the SMAART consortium including members such as University College London and the University of Oxford, has been published today in the peer-reviewed journal Nature Communications, following independent peer review. The manuscript was submitted in June 2026 and made available ahead of peer review as a preprint via Research Square.